Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human Gene Therapy, that by delivering additional mRNA encoding viral interferon inhibitors with the saRNA to human fibroblasts, vaccine expression could be rescued. These findings could be exploited to increase bioavailability of encoded antigens, reduce the effective dose and thus manufacturing costs in all saRNA applicational fields.
Citation: Beissert, T., Koste, L., Perkovic, M., Walzer, K.C., Erbar, S., Selmi, A. Diken, M., Kreiter, S., Türeci, Ö., Sahin, U. Improvement of in vivo expression of genes delivered by self-amplifying RNA using Vaccinia Virus immune evasion proteins. Hum Gene Ther. 2017. doi: 10.1089/hum.2017.121